Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00962091 · ClinicalTrials.gov registry record · Phase 1
Study of MLN8237 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00962091 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 53 participants.
The verdict
NCT00962091, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purposes of this study were to estimate the relative (Rel) bioavailability (BA) of an oral solution (OS) formulation of alisertib in reference to a powder-in-capsule (PIC) formulation, to characterize the effect of food on the single-dose pharmacokinetics (PK) of alisertib OS and enteric-coated tablets (ECT), to characterize the multiple-dose safety, tolerability, and steady-state PK of alisertib administered as an OS, and to characterize the multiple-dose safety and tolerability of alisertib administered as an ECT.
Interventions
- DRUG Alisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2009-09-25 |
| Est. Completion | 2014-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00962091
The ClinicalTrials.gov registry entry for NCT00962091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alisertib is the first listed.
NCT00962091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00962091 about?
NCT00962091 is a clinical study titled "Study of MLN8237 in Participants With Advanced Solid Tumors". The purposes of this study were to estimate the relative (Rel) bioavailability (BA) of an oral solution (OS) formulation of alisertib in reference to a powder-in-capsule (PIC) formulation, to characterize the effect of food on the single-dose pharmacokinetics (PK) of alisertib OS and enteric-coated ...
What is the current status of trial NCT00962091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2009-09-25. Estimated completion is 2014-07-01.
What interventions are being tested in trial NCT00962091?
The interventions under investigation include: Alisertib (DRUG).
Who is sponsoring clinical trial NCT00962091?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.